NASDAQ · Medical - Diagnostics & Research

PRE (PRE) Stock

$18.64 -3.12% NASDAQ: PRE Healthcare

Valuation

MetricValue
Price$18.64
Market Cap$316.89M
P/E Ratio-5.83
P/B Ratio1.51
P/S Ratio2.74
EPS (TTM)$-2.68
52-Week High$23.63
52-Week Low$7.17
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-21.71%
ROA-18.63%
ROCE-21.71%
Gross Margin-42.39%
Operating Margin-41.30%
Net Margin-61.32%
Debt/Equity0.01
Current Ratio2.96

Annual Financials (USD)

Metric20212022202320242025
Revenue$13.0M$13.0M$22.0M$31.0M$92.0M
Operating Profit$-57.0M$-66.0M$-52.0M$-48.0M$-38.0M
Net Profit$-174.0M$-190.0M$-63.0M$-46.0M$-38.0M
EPS$-47.04$-37.57$-5.58$-3.64$-2.68
Op Margin-452.1%-501.5%-238.7%-157.2%-41.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$149.0M$312.0M$254.0M$214.0M$204.0M
Total Liabilities$549.0M$69.0M$44.0M$42.0M$29.0M
Cash$35.0M$147.0M$46.0M$52.0M$32.0M
Borrowings$492.0M$7.0M$2.0M$6.0M$2.0M

Latest News

PRE Continues to Exceed Expectations and Receive Preferential Financing Zacks Small Cap Research · Jul 15, 2026 Sector Update: Healthcare Stocks Fall Late Afternoon MT Newswires · Jul 14, 2026 Sector Update: Healthcare MT Newswires · Jul 14, 2026 Market Chatter: IM8, Co-Founded by Prenetics and David Beckham, Gets General Catalyst Financing MT Newswires · Jul 14, 2026 Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF) GlobeNewswire · Jul 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$13.0M$15.0M$-14.0M$-29.0M$-22.0M
Investing Cash Flow$-33.0M$-52.0M$-84.0M$37.0M$-36.0M
Financing Cash Flow$5.0M$145.0M$-1.0M$-1.0M$-3.0M
Net Cash Flow$21.0M$111.0M$-101.0M$7.0M$-20.0M
Free Cash Flow$2.0M$8.0M$-15.0M$-30.0M$-22.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-8.44%
Quick Ratio2.76
Interest Coverage—
Return 1Y125.03%
Return 3Y59.05%
Return 5Y-83.21%

Ownership

Insiders Held14.17%
Institutions Held12.84%
Institutions Float Held14.95%
Institutional HolderSharesReport Date
Prudential PLC427,9632026-03-31
Aspex Management (HK) Ltd346,1502026-03-31
Tenzing Global Management, Llc200,0002026-03-31
Goldman Sachs Group Inc193,5832026-03-31
Millennium Management Llc192,6002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMPArmata Pharmaceuticals, Inc. $4.64 -0.43% -0.60 $170.34M 0.00%
ATLN $0.90 +0.00% -1.31 $73.17M 0.00%
CDXS $1.47 -2.00% -5.06 $133.62M 0.00%
IMDXInsight Molecular Diagnostics Inc. $4.70 -0.84% -3.13 $151.76M 0.00%
MXCT $1.18 +6.31% -2.55 $126.40M 0.00%

About PRE

PRE is led by CEO Sheng Wu Yeung, publicly traded since 2021.

PRE stock trades at $18.64 with a market capitalization of $316.89M. The stock is valued at a price-to-earnings (P/E) ratio of -5.83, price-to-book of 1.51, price-to-sales of 2.74. Over the past 52 weeks the stock has ranged between $7.17 and $23.63, and currently trades 21.1% below its 52-week high.

On profitability, PRE generates a return on equity (ROE) of -21.71%, return on capital employed of -21.71%, an operating margin of -41.30%, a net profit margin of -61.32%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides